23 Jul

Cypher Genomics Named a San Diego “COOL Company” by San Diego Venture Group

SDVG Cool Companies 2015Out of 160 applicants this year, Cypher Genomics is proud to be among the select group of this year’s 31 COOL Companies.

Each year, the San Diego Venture Group selects a small group of nominated start-ups by designating them “COOL Companies”. What does being “COOL” mean? Small or large, SDVG’s COOL Companies represent the innovation taking place in San Diego’s major industries, including life science, technology and finance.

Cypher Genomics, founded from the Scripps Translational Science Institute (STSI), has developed rapid, automated software that turns billions of gigabases of sequencing data into answers. While sequencing a human genome can cost less than $1,000, the clinical interpretation can be worth millions.

Cypher recently collaborated with Sequenom and Celgene to use Cypher’s genomic interpretation technologies to improve clinical diagnostics and drug development, respectively. Cypher also has a number of research collaborations, including with UPenn/CurePSP and Clinic for Special Children, to help find genetic causes of rare diseases.

The 2015 COOL Companies will be featured at the SDVG’s Annual Venture Summit on September 24- 25th at the Manchester Grand Hyatt in Downtown San Diego.  The event draws an attendance of over 700 people, including around 100 venture capitalists.  Interested in meeting Cypher and the rest of the COOL Companies?

Register for the Venture Summit here.

See the full list of 2015 COOL Companies.

Cypher Genomics was also recently named one of San Diego’s MetroConnect Prize Winners. Read more here.

Share this
01 Jul

Cypher Genomics Named One of San Diego’s MetroConnect Prize Winners

The MetroConnect Prize is part of San Diego Regional Economic Development Corporation’s (EDC’s) Go Global San Diego Initiative, whose mission is to aid in increasing the region’s economic competitiveness and prosperity by helping companies strategically expand to implement global economic engagement.

Funded by JPMorgan Chase & Co., MetroConnect grants 15 winning company, including Cypher, with $10,000 in matching funds to cover up to 50% of the costs associated with the company’s next step to going global. Read more here about why companies are going global.

Why Cypher Genomics?

The award was announced today at a press conference featuring San Diego Mayor Kevin Faulconer and other key elected officials and business leaders. Cypher’s President and COO, Adam Simpson, accepted the award and spoke at the event.

Simpson explained why San Diego is the city for genomics, with Cypher’s neighbors including industry leaders The Scripps Research Institute, from which Cypher was founded, Hank Nordhoff, former chairman and CEO of Gen-Probe, who leads Cypher’s board of directors to the teams at Celgene, Illumina, Lockheed Martin and Sequenom, who are among Cypher’s collaborators.

Although San Diego is one of the field’s key “hometowns”, genomics is a global industry with global impact, which means San Diego has the potential to be the center of advancing genomics for the world.

Cypher is working to solve a large problem facing the genomics industry – genome interpretation. How do you take the 3.2 billion base pairs that makes up your genome and turn that into information that can be used to deliver better healthcare?

With Cypher’s genome interpretation technology, there is an opportunity to improve how diseases are diagnosed and enable more successful development by pharmaceutical companies by getting the right drug to the right patient. Cypher’s technology can also help advance large-scale genomics studies, like the UK’s 100,000 Genome Project.

Why #GoGlobal?

Cypher plans to use the prize from MetroConnect to continue to advance business development efforts around the globe including in United Kingdom, Japan and China, countries that can benefit from using genomics to improve health and healthcare.

Read more about the MetroConnect Prize via UT San Diego

Share this
22 Jun

Cypher is Proud to be a BeHEARD Technology Sponsor

This spring academic researchers, charitable foundations, and families affected by rare diseases submitted their proposals for the Rare Genomics Institute’s BeHEARD (Helping Empower and Accelerate Research Discoveries) science challenge. Their goal: to win access to leading-edge technologies to advance their research projects in rare diseases. Applicants were able to select the prize that would most benefit their studies, from a list that includes custom animal disease models, molecular biology tools, and data analysis software.

Cypher Genomics is proud to be a BeHEARD Ultimate Technology Sponsor. We’re offering up to 100 whole-genome sequence analyses or 200 exome panel analyses to the winning team. If the winning proposal doesn’t require all 100 or 200 analyses, we’ll divide the prize among multiple winners.

“We are committed to supporting rare disease research and we believe there are many fantastic researchers out there who could benefit from our experience identifying novel disease genes in previously unknown or misunderstood disorders,” said Ashley Van Zeeland, Ph.D., Cypher co-founder and chief executive officer. “All the winner will need to do is submit a variant file with their whole-genome or exome sequencing data, and Mantis™, – our interpretation platform with a user-friendly web interface – will help them find variations relevant to their research or clinical application.”

Research proposals are currently in review by the Rare Genomics Institute’s scientific advisors, as well as technology experts from Cypher and other sponsoring companies. We are looking for ideas that have great potential to advance research and find treatments for rare diseases as well as a realistic chance for success and a good fit with the available technology prizes. Once we’ve narrowed it down, final winners will be selected by Facebook voting (more info to come on how vote) and announced August 5, 2015.

Connect on social media

Twitter: @RareGenomics, #BeHEARD2015, #raredisease
Facebook: facebook.com/raregenomics
LinkedIn: linkedin.com/company/rare-genomics-institute

Rare diseases are defined as conditions that affect fewer than 200,000 Americans. The National Institutes of Health estimates there are approximately 6,800 rare diseases known, most of which are inherited genetic disorders. The Rare Genomics Institute helps families of affected children connect with researchers studying genomics and rare diseases. Through crowdfunding, the Rare Genomics Institute provides these unique teams with access to sophisticated technologies and resources to advance research and treatments.

Share this